BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 18424742)

  • 1. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells.
    Baritaki S; Suzuki E; Umezawa K; Spandidos DA; Berenson J; Daniels TR; Penichet ML; Jazirehi AR; Palladino M; Bonavida B
    J Immunol; 2008 May; 180(9):6199-210. PubMed ID: 18424742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1.
    Baritaki S; Huerta-Yepez S; Sakai T; Spandidos DA; Bonavida B
    Mol Cancer Ther; 2007 Apr; 6(4):1387-99. PubMed ID: 17431117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1.
    Huerta-Yepez S; Vega M; Escoto-Chavez SE; Murdock B; Sakai T; Baritaki S; Bonavida B
    Nitric Oxide; 2009 Feb; 20(1):39-52. PubMed ID: 18778787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis.
    Martínez-Paniagua MA; Baritaki S; Huerta-Yepez S; Ortiz-Navarrete VF; González-Bonilla C; Bonavida B; Vega MI
    Cell Cycle; 2011 Aug; 10(16):2792-805. PubMed ID: 21822052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 up-regulation.
    Baritaki S; Katsman A; Chatterjee D; Yeung KC; Spandidos DA; Bonavida B
    J Immunol; 2007 Oct; 179(8):5441-53. PubMed ID: 17911631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization.
    Baritaki S; Yeung K; Palladino M; Berenson J; Bonavida B
    Cancer Res; 2009 Nov; 69(21):8376-85. PubMed ID: 19843864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
    Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
    Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway.
    Jane EP; Premkumar DR; Pollack IF
    Mol Cancer Ther; 2011 Jan; 10(1):198-208. PubMed ID: 21220502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells.
    Khanbolooki S; Nawrocki ST; Arumugam T; Andtbacka R; Pino MS; Kurzrock R; Logsdon CD; Abbruzzese JL; McConkey DJ
    Mol Cancer Ther; 2006 Sep; 5(9):2251-60. PubMed ID: 16985059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteasome inhibitors enhance TRAIL-induced apoptosis through the intronic regulation of DR5: involvement of NF-kappa B and reactive oxygen species-mediated p53 activation.
    Chen JJ; Chou CW; Chang YF; Chen CC
    J Immunol; 2008 Jun; 180(12):8030-9. PubMed ID: 18523266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of the TNF-alpha autocrine-paracrine loop, via NF-kappaB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis.
    Huerta-Yepez S; Vega M; Garban H; Bonavida B
    Clin Immunol; 2006 Sep; 120(3):297-309. PubMed ID: 16784892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Butein sensitizes human hepatoma cells to TRAIL-induced apoptosis via extracellular signal-regulated kinase/Sp1-dependent DR5 upregulation and NF-kappaB inactivation.
    Moon DO; Kim MO; Choi YH; Kim GY
    Mol Cancer Ther; 2010 Jun; 9(6):1583-95. PubMed ID: 20515942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib.
    Voortman J; Resende TP; Abou El Hassan MA; Giaccone G; Kruyt FA
    Mol Cancer Ther; 2007 Jul; 6(7):2103-12. PubMed ID: 17620439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis.
    Song JH; Kandasamy K; Kraft AS
    J Biol Chem; 2008 Sep; 283(36):25003-13. PubMed ID: 18599488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BAP1 and YY1 regulate expression of death receptors in malignant pleural mesothelioma.
    Ishii Y; Kolluri KK; Pennycuick A; Zhang X; Nigro E; Alrifai D; Borg E; Falzon M; Shah K; Kumar N; Janes SM
    J Biol Chem; 2021 Nov; 297(5):101223. PubMed ID: 34597666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma.
    Perez LE; Parquet N; Meads M; Anasetti C; Dalton W
    Eur J Haematol; 2010 Mar; 84(3):212-22. PubMed ID: 19922463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways.
    Seki N; Toh U; Sayers TJ; Fujii T; Miyagi M; Akagi Y; Kusukawa J; Kage M; Shirouzu K; Yamana H
    Mol Cancer Ther; 2010 Jun; 9(6):1842-51. PubMed ID: 20515944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region.
    Kandasamy K; Kraft AS
    Mol Cancer Ther; 2008 May; 7(5):1091-100. PubMed ID: 18483298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells.
    Kabore AF; Sun J; Hu X; McCrea K; Johnston JB; Gibson SB
    Apoptosis; 2006 Jul; 11(7):1175-93. PubMed ID: 16699949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of ataxia telangiectasia mutated kinase activity enhances TRAIL-mediated apoptosis in human melanoma cells.
    Ivanov VN; Zhou H; Partridge MA; Hei TK
    Cancer Res; 2009 Apr; 69(8):3510-9. PubMed ID: 19351839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.